|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Mr. Lars Fruergaard Jorgensen||Pres, CEO & Member of Management Board||35,7M||N/A||1966|
|Mr. Karsten Munk Knudsen||Exec. VP, CFO & Member of the Management Board||13,2M||N/A||1971|
|Mr. Henrik Ehlers Wulff||Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board||13,9M||N/A||1970|
|Ms. Camilla Sylvest||Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board||13,2M||N/A||1972|
|Ms. Monique Carter||Exec. VP, Head of People & Organisation and Member of Management Board||10M||N/A||1973|
|Mr. Maziar Mike Doustdar||Exec. VP, Head of International Operations & Member of the Management Board||N/A||N/A||1970|
|Mr. Douglas J. Langa||Exec. VP, Head of North America Operations & Member of Management Board||N/A||N/A||1966|
|Mr. Ludovic Helfgott||Exec. VP, Head of Biopharm & Member of Management Board||N/A||N/A||1974|
|Mr. Martin Holst Lange||Exec. VP, Head of Devel. & Member of the Management Board||N/A||N/A||N/A|
|Mr. Marcus Schindler Ph.D.||Exec. VP of Research & Early Devel., CSO and Member of the Management Board||N/A||N/A||1966|
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
El ISS Governance QualityScore de Novo Nordisk A/S, a día 26 de septiembre de 2021, es 3. Las puntuaciones base son Auditoría: 2; Tablero: 3; Derechos de los accionistas: 9; Compensación: 1.